Meningioma

P=N/A, N=21, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Aug 2025 --> Aug 2027

This review comprehensively describes the physiological roles of TRAF7 and the pathophysiology of clinical conditions with TRAF7 alterations. We highlight important directions for future work to improve our understanding of the mechanisms underlying TRAF7 related disease, identify prognostic biomarkers that help guide clinical decision making, and potentially identify novel therapeutic targets to expand our treatment options for these patients.

Sintilimab failed to improve PFS-6 in both grade 1 and grade 2/3 recurrent/progressive meningiomas in this single-arm, single-center, and small-sample trial. When evaluating PD-1 inhibitor treatment for recurrent/progressive meningioma patients, who generally have a longer expected survival and high TMB, the use of the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria may be more appropriate to avoid overlooking potential clinical benefits.

The patient subsequently underwent chemotherapy with temozolomide and external beam radiation therapy with 60 Gy over 30 fractions...The patient was subsequently placed on bevacizumab...Additionally, there is difficulty in differentiating these tumors from meningiomas, with resultant misdiagnosis and management. It is critical to inform readers of its presence and emphasize the importance of its consideration in the differential diagnosis of dural-based tumors.

In this cohort, demographic, clinical, or radiological features did not reliably predict CDKN2A/B deletion. Several deletion-positive meningiomas were classified as grade 1 or 2, underscoring the disconnect between morphology and molecular grading. These findings support universal CDKN2A/B testing for accurate WHO classification and risk assessment.

Digital PR H-score assessment confirmed the inverse association between PR expression and WHO grade, as well as its correlation with proliferative activity. Using an FDA-cleared algorithm originally developed for breast carcinoma, this method provides objective and reproducible evaluation in meningiomas.

In this large cohort with extended follow-up, STR patients exhibited a second recurrence peak at 7 to 10 years postoperatively. Adjuvant GKRS showed long-term benefit, supporting its selective use and long-term surveillance beyond 10 years.

This study demonstrates that 99 mTc-HYNIC-octreotide SPECT/CT imaging is an effective method for detecting somatostatin receptor expression in brain tumors, offering a low-cost and accessible alternative to more enhanced imaging techniques, both meningioma and glial tumors express somatostatin receptors, but receptor expression is significantly higher in meningioma.

Our results suggest that MUC4 is associated with higher grades of meningiomas and may have a negative impact on prognosis and recurrence rates, potentially making it a target for an agent with mucolytic effects that can help overcome chemoresistance in aggressive meningiomas. On the other hand, the expression of Caspase-3 correlates with the grade of differentiation and certain histotypes and may be considered as an ideal target for meningioma therapeutic regimens.

Clinically, these tumors display low-grade behavior and DNA methylation profiles consistent with benign subtypes. Our findings identify a meningioma subgroup with distinct genetic, transcriptomic, and clinical features, expanding the molecular classification of meningiomas and opening new avenues for targeted treatment strategies.

P=N/A, N=2500, Recruiting, University Health Network, Toronto | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026